Review of recent evidence: Potential interaction between clopidogrel and proton pump inhibitors

American Journal of Health-System Pharmacy

Volumn 66, Issue 23, 2009, Pages 2117-2122

  Last, Esther J ^a   Sheehan, Amy Heck ^b  

^a INDIANA UNIVERSITY HEALTH   (United States)

^b PURDUE UNIVERSITY   (United States)

Author keywords

Cardiovascular diseases; Clopidogrel; Drug interactions; Gastrointestinal drugs; Platelet aggregation inhibitors; Toxicity

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PLACEBO; PROTON PUMP INHIBITOR; RABEPRAZOLE;

CARDIOLOGY; CLINICAL TRIAL; DRUG INTERACTION; GASTROINTESTINAL HEMORRHAGE; HUMAN; PRIORITY JOURNAL; REVIEW; THROMBOCYTE AGGREGATION;

EID: 73449123673     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp090282     Document Type: Review

References (27)

1. Plavix (clopidogrel bisulfate) package insert. Bridgewater, NJ: Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership; 2009 May.
2. Anderson JL, Adams CD, Antman EM et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/ Non-ST-Elevation Myocardial Infarction). Circulation. 2007; 116:e148-304. [Erratum, Circulation. 2008; 117:e180.]
3. King SB 3rd, Smith SC Jr, Hirshfeld JW Jr et al. 2007 focused update of the ACC/ AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the 2005 ACC/AHA/SCAI Guideline Update for Percutaneous Coronary Intervention. Circulation. 2008; 117:261-295 [Erratum, Circulation. 2008; 117:el61.]
4. Bhatt DL, Scheiman J, Abraham NS et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation. 2008; 118:1894-909.
5. Lanza FL, Chan FK, Quigley EM; for the Practice Parameters Committee of the American College of Gastroenterology. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol. 2009; 104:728-738
6. Taha AS, McCloskey C, Prasad R et al. Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo- controlled trial. Lancet. 2009; 374:119-125
7. Tan VP, Yan BP, Kiernan TJ et al. Risk and management of upper gastrointestinal bleeding associated with prolonged dual- antiplatelet therapy after percutaneous coronary intervention. Cardiovasc Revasc Med. 2009; 10:36-44.
8. Aubert RE, Epstein RS, Teagarden JR et al. Proton pump inhibitors effect on clopidogrel effectiveness: the Clopidogrel Medco Outcomes Study. Circulation. 2008; 118:S-815:abstract3998.
9. American Heart Association. American College of Cardiology/American College of Gastroenterology/American Heart Association joint comment on studies regarding possible interaction of clopidogrel and proton pump inhibitors. http://americanheart.mediaroom.com/ index.php?s=43&item=611 (accessed 2009 May 8).
10. Food and Drug Administration. Early communication about an ongoing safety review of clopidogrel bisulfate (marketed as Plavix). www.fda.gov/Drugs/ DrugSafety/PostmarketDrugSafety InformationforPatientsandProviders/ DrugSafetylnformationforHealthcare Professionals/ucm079520.htm (accessed 2009 Jul 30).
11. Mega JL, Close SL, Wiviott SD et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009; 360:354-362
12. Li XQ, Andersson TB, Ahlström M et al. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004; 32:821-827
13. Simon T, Verstuyft C, Mary-Krause M et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009; 360:363-375
14. Guard M, Arnaud B, Le Gal G et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated to aspirin. J Thromb Haemost. 2006; 4:2508-2509 Letter. (Pubitemid 44575451)
15. Gilard M, Arnaud B, Cornily JC et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole clopidogrel Aspirin) study. J Am Coll Cardiol. 2008; 51:256-260
16. Síller-Matula JM, Spiel AO, Lang IM et al. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J. 2009; 157:148.e1-5
17. Sibbing D, Morath T, Stegherr J et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost. 2009; 101:714-719
18. Pezalla E, Day D, Pulliadath I. Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors. J Am Coll Cardiol. 2008; 52:1037-1039 Letter.
19. Juurlink DN, Gomes T, Ko DT et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ. 2009; 180:713-718
20. Ho PM, Maddox TM, Wang L et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009; 301:937-944
21. Wood S. Possible "class effect" for proton-pump inhibitors on top of clopidogrel therapy. www.theheart.org/ article/967075.do (accessed 2009 Jul 30).
22. Society for Cardiovascular Angiography and Interventions. SCAI statement on "a national study of the effect of individual proton pump inhibitors on cardiovascular outcomes in patients treated with clopidogrel following coronary stenting: the Clopidogrel Medco Outcomes Study.www.scai.org/drltl.aspx?PAGE-ID= 5870 (accessed 2009 Jul 30).
23. Stanek EJ, Aubert RE, Flockhart DA et al. A national study of the effect of individual proton pump inhibitors on cardiovascular outcomes in patients treated with clopidogrel following coronary stenting: the Clopidogrel Medco Outcomes Study, www.theheart.org/display- Item.do?primaryKey=967345&type=ppt (accessed 2009 Jul 30).
24. Dunn SP, Macaulay TE, Brennan DM et al. Baseline proton pump inhibitor use is associated with increased cardiovascular events with and without the use of clopidogrel in the CREDO trial. Circulation. 2008; 118:S-815:abstract 3999.
25. National Institutes of Health. Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1). http://clinicaltrials. gov/ct2/show/ NCT00557921 (accessed 2009 Jul 30).
26. National Institutes of Health. Evaluation of the Influence of Statins and Proton Pump Inhibitors on Clopidogrel Antiplatelet Effects (SPICE). http:// clinicaltrials.gov/ct2/show/NCT 00930670 (accessed 2009 Jul 30).
27. O'Donoghue ML, Braunwalkd E, Antman EM et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomized trials. Lancet. 2009 Sep 1. Electronically published ahead of print.